Literature DB >> 3125001

Clinical pharmacokinetics of factor VIII in patients with classic haemophilia.

A Messori1, G Longo, M Matucci, M Morfini, P L Ferrini.   

Abstract

Studies of Factor VIII pharmacokinetics in haemophiliacs can be classified into 2 groups depending on whether single-dose or multiple-dose Factor VIII curves are used. This review analyses information published so far in both these areas, with particular emphasis on the choice of appropriate models for pharmacokinetic analysis. Single-dose studies of Factor VIII kinetics have previously used a wide variety of methods for pharmacokinetic analysis (empirical methods of Factor VIII level prediction, graphical techniques for semilog analysis, 1-compartment and 2-compartment models). However, Factor VIII poses unique problems to the pharmacokineticist because decay curves can be either monophasic (monoexponential) or biphasic (biexponential) for unknown reasons, and because Factor VIII concentrations are generally subject to significant assay error. Problems of compartmental analysis that occurred in previous studies are highlighted, and a model-independent non-compartmental approach for analysing Factor VIII curves is proposed. To date, fewer data have been published on multiple-dose kinetics of Factor VIII. From a clinical point of view, repeated-dose regimens are most commonly required in patients undergoing surgery and in patients with severe bleeding. A fairly well defined 'therapeutic window' of optimal Factor VIII plasma concentrations has been identified, particularly in surgical patients. This fact has spurred research aimed at applying to haemophilia patients the pharmacokinetic dosing methods commonly used for therapeutic monitoring of drugs (e.g. Bayesian method for dosage individualization). A few papers have already been published in this field, and this review summarises problems encountered by previous investigators, and evaluates comparatively the pharmacokinetic methods used.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3125001     DOI: 10.2165/00003088-198713060-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  54 in total

1.  Haemophilia in Sweden. VI. Treatment of haemophilia A with the human antihaemophilic factor preparation (fraction I--0).

Authors:  I M NILSSON; M BLOMBACK; O RAMGREN
Journal:  Acta Med Scand Suppl       Date:  1962

2.  Plasma clearance rates of coagulation factors VIII and IX in factor-deficient individuals.

Authors:  D A Noe; W R Bell; P M Ness; J Levin
Journal:  Blood       Date:  1986-04       Impact factor: 22.113

3.  Comparison of two pharmacokinetic techniques for individualizing factor VIII dosage in haemophilia patients.

Authors:  M Morfini; T H Grasela; G Longo; M Matucci; A Messori; S Vannini; P Rossi-Ferrini
Journal:  Haematologica       Date:  1985 Sep-Oct       Impact factor: 9.941

4.  A Bayesian feedback method of aminoglycoside dosing.

Authors:  M E Burton; D C Brater; P S Chen; R B Day; P J Huber; M R Vasko
Journal:  Clin Pharmacol Ther       Date:  1985-03       Impact factor: 6.875

5.  Factor VIII standardisation.

Authors:  T W Barrowcliffe; D P Thomas
Journal:  Lancet       Date:  1981-12-12       Impact factor: 79.321

6.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

7.  Kinetic evaluation of four Factor VIII concentrates by model-independent methods.

Authors:  M Matucci; A Messori; G Donati-Cori; G Longo; S Vannini; M Morfini; E Tendi; P L Rossi-Ferrini
Journal:  Scand J Haematol       Date:  1985-01

8.  In vivo effectiveness of a high-yield factor VIII concentrate prepared in a blood bank.

Authors:  G Rock; R K Smiley; P Tittley; D S Palmer
Journal:  N Engl J Med       Date:  1984-08-02       Impact factor: 91.245

9.  Heparin small pool high yield purified factor VIII: in vivo recovery and half-life of routinely produced freeze-dried concentrate.

Authors:  C T Smit Sibinga; S M Daenen; G W van Imhoff; A Maas; P C Das
Journal:  Thromb Haemost       Date:  1984-02-28       Impact factor: 5.249

10.  Individualization of Factor VIII dosage.

Authors:  A Messori; G Longo; M Morfini; G Donati-Cori; M Matucci; S Ruffo; E Tendi; S Vannini
Journal:  J Clin Hosp Pharm       Date:  1984-06
View more
  10 in total

Review 1.  Bayesian parameter estimation and population pharmacokinetics.

Authors:  A H Thomson; B Whiting
Journal:  Clin Pharmacokinet       Date:  1992-06       Impact factor: 6.447

2.  Quality control programme for the preparation of small-pool lyophilized heat-treated cryoprecipitates.

Authors:  D P Allersma; F Swüste; E Briët; J A Van der Does
Journal:  Pharm Weekbl Sci       Date:  1991-02-22

3.  Multi-variate analysis of factors governing the pharmacokinetics of exogenous factor VIII in haemophiliacs.

Authors:  A Messori; G Longo; M Morfini; S Cinotti; E Filimberti; G Giustarini; P Rossi Ferrini
Journal:  Eur J Clin Pharmacol       Date:  1988       Impact factor: 2.953

Review 4.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

5.  Phosphatidylinositol containing lipidic particles reduces immunogenicity and catabolism of factor VIII in hemophilia a mice.

Authors:  Aaron Peng; Robert M Straubinger; Sathy V Balu-Iyer
Journal:  AAPS J       Date:  2010-06-02       Impact factor: 4.009

6.  Comparative pharmacokinetics of plasma- and albumin-free recombinant factor VIII in children and adults: the influence of blood sampling schedule on observed age-related differences and implications for dose tailoring.

Authors:  S Björkman; V S Blanchette; K Fischer; M Oh; G Spotts; P Schroth; S Fritsch; L Patrone; B M Ewenstein; P W Collins
Journal:  J Thromb Haemost       Date:  2010-04       Impact factor: 5.824

7.  Pharmacokinetics of factor VIII in humans. Obtaining clinically relevant data from comparative studies.

Authors:  S Björkman; M Carlsson; E Berntorp; P Stenberg
Journal:  Clin Pharmacokinet       Date:  1992-05       Impact factor: 6.447

8.  Pharmacokinetics and dose requirements of factor VIII over the age range 3-74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A.

Authors:  Sven Björkman; Anna Folkesson; Siv Jönsson
Journal:  Eur J Clin Pharmacol       Date:  2009-06-26       Impact factor: 2.953

9.  Microencapsulation Approach for Orally Extended Delivery of Glipizide: In vitro and in vivo Evaluation.

Authors:  A Abdelbary; N A El-Gendy; A Hosny
Journal:  Indian J Pharm Sci       Date:  2012-07       Impact factor: 0.975

Review 10.  The History of Clotting Factor Concentrates Pharmacokinetics.

Authors:  Massimo Morfini
Journal:  J Clin Med       Date:  2017-03-20       Impact factor: 4.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.